Most importantly, emapalumab administration was able to completely protect mice from acute CRS, as all mice treated with emapalumab survived behind the timeline of the experimental plan (15 days), while untreated mice died within 7 days after CAR.CD19-T cell infusion. This evidence concerns the gene CD19 and congenital rubella syndrome.